



## Clinical trial results:

### A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction And Maintenance Treatment For Patients With Moderately to Severely Active Crohn's Disease

#### Summary

EudraCT number	2014-003824-36
Trial protocol	SE EE LT LV HU DE ES CZ NL AT SK BE FR HR RO IT
Global end of trial date	07 September 2021

#### Results information

Result version number	v1
This version publication date	17 September 2022
First version publication date	17 September 2022

#### Trial information

##### Trial identification

Sponsor protocol code	GA29144
-----------------------	---------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03850535
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124., Basel, Switzerland, CH-4070
Public contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 September 2021
Is this the analysis of the primary completion data?	Yes
Primary completion date	07 September 2021
Global end of trial reached?	Yes
Global end of trial date	07 September 2021
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

A study evaluating the efficacy, safety, and tolerability of etrolizumab compared with placebo during induction and maintenance treatment of moderately to severely active Crohn's Disease (CD)

Protection of trial subjects:

The study was conducted in accordance with the principles of the "Declaration of Helsinki" and Good Clinical Practice (GCP) guidelines according to the regulations and procedures described in the protocol.

Background therapy: -

Evidence for comparator:

No active control

Actual start date of recruitment	20 March 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 1
Country: Number of subjects enrolled	Austria: 15
Country: Number of subjects enrolled	Australia: 42
Country: Number of subjects enrolled	Belgium: 11
Country: Number of subjects enrolled	Brazil: 40
Country: Number of subjects enrolled	Bulgaria: 8
Country: Number of subjects enrolled	Canada: 64
Country: Number of subjects enrolled	Switzerland: 9
Country: Number of subjects enrolled	Czechia: 55
Country: Number of subjects enrolled	Germany: 29
Country: Number of subjects enrolled	Spain: 36
Country: Number of subjects enrolled	Estonia: 4
Country: Number of subjects enrolled	France: 58
Country: Number of subjects enrolled	United Kingdom: 34
Country: Number of subjects enrolled	Croatia: 9
Country: Number of subjects enrolled	Hungary: 38
Country: Number of subjects enrolled	Israel: 22
Country: Number of subjects enrolled	Italy: 22
Country: Number of subjects enrolled	Korea, Republic of: 34
Country: Number of subjects enrolled	Lithuania: 6

Country: Number of subjects enrolled	Latvia: 4
Country: Number of subjects enrolled	Mexico: 4
Country: Number of subjects enrolled	Netherlands: 21
Country: Number of subjects enrolled	New Zealand: 22
Country: Number of subjects enrolled	Poland: 60
Country: Number of subjects enrolled	Romania: 13
Country: Number of subjects enrolled	Russian Federation: 69
Country: Number of subjects enrolled	Serbia: 15
Country: Number of subjects enrolled	Slovakia: 13
Country: Number of subjects enrolled	Turkey: 12
Country: Number of subjects enrolled	Ukraine: 39
Country: Number of subjects enrolled	United States: 221
Country: Number of subjects enrolled	South Africa: 5
Worldwide total number of subjects	1035
EEA total number of subjects	402

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	997
From 65 to 84 years	38
85 years and over	0

## Subject disposition

### Recruitment

#### Recruitment details:

A total of 2305 patients were screened and 1035 patients were randomized into the induction phase. Subject enrollment was sequential across Cohorts 1, 2, and 3. The final sample size for the pivotal induction Cohort 3 was lower than the 496 patients planned per the final protocol due to the early closure of the study.

### Pre-assignment

#### Screening details:

A total of 2305 patients were screened and 1035 patients were randomized into the induction phase. Subject enrollment was sequential across Cohorts 1, 2, and 3. The final sample size for the pivotal induction Cohort 3 was lower than the 496 patients planned per the final protocol due to the early closure of the study.

### Period 1

Period 1 title	Induction Phase
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer, Data analyst, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo Cohort 1

#### Arm description:

Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.

Arm type	Placebo
Investigational medicinal product name	Two SC injections of etrolizumab-matching placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

#### Dosage and administration details:

Placebo

<b>Arm title</b>	Etrolizumab 105mg Cohort 1
------------------	----------------------------

#### Arm description:

Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Arm type	Experimental
Investigational medicinal product name	Etrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

#### Dosage and administration details:

One SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week

<b>Arm title</b>	Etrolizumab 210mg Cohort 1
Arm description:	
Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one SC injection of etrolizumab (210 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.	
Arm type	Experimental
Investigational medicinal product name	Etrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
One subcutaneous (SC) injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.	
<b>Arm title</b>	Etrolizumab 105mg Cohort 2

Arm description:	
Cohort 2 is enrolling participants after Cohort 1 and is considered a "feeder" cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.	
Arm type	Experimental
Investigational medicinal product name	Etrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
One SC injection of open-label etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.	
<b>Arm title</b>	Etrolizumab 210mg Cohort 2

Arm description:	
Cohort 2 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (210 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.	
Arm type	Experimental
Investigational medicinal product name	Etrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
one SC injection of open-label etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking for the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.	
<b>Arm title</b>	Placebo Cohort 3

Arm description:	
Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction	

Phase. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.

Arm type	Placebo
Investigational medicinal product name	Etrolizumab-matching placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week

<b>Arm title</b>	Etrolizumab 105mg Cohort 3
------------------	----------------------------

Arm description:

Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Arm type	Experimental
Investigational medicinal product name	Etrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

One SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

<b>Arm title</b>	Etrolizumab 210mg Cohort 3
------------------	----------------------------

Arm description:

Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm received one SC injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Arm type	Experimental
Investigational medicinal product name	Etrolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

One SC injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

<b>Number of subjects in period 1</b>	Placebo Cohort 1	Etrolizumab 105mg Cohort 1	Etrolizumab 210mg Cohort 1
Started	59	120	121
Induction Phase	59	120	121
Completed	52	104	108
Not completed	7	16	13
Consent withdrawn by subject	1	2	4
Physician decision	-	-	1
withdrawal, roll over to a different study	-	-	-
Adverse event, non-fatal	2	4	1
Lack of calculation	-	-	-
Non-compliance	-	1	3
Lost to follow-up	1	-	-
Sponsor decision	-	1	2
Technical reason	-	-	-
Lack of efficacy	3	6	2
Protocol deviation	-	2	-

<b>Number of subjects in period 1</b>	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2	Placebo Cohort 3
Started	176	174	97
Induction Phase	176	174	97
Completed	141	145	80
Not completed	35	29	17
Consent withdrawn by subject	6	7	4
Physician decision	4	-	2
withdrawal, roll over to a different study	-	-	-
Adverse event, non-fatal	2	5	2
Lack of calculation	-	-	-
Non-compliance	1	3	-
Lost to follow-up	1	-	-
Sponsor decision	-	-	-
Technical reason	1	-	-
Lack of efficacy	17	14	8
Protocol deviation	3	-	1

<b>Number of subjects in period 1</b>	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3
Started	143	145
Induction Phase	143	145
Completed	118	114
Not completed	25	31

Consent withdrawn by subject	3	6
Physician decision	1	-
withdrawal, roll over to a different study	1	-
Adverse event, non-fatal	-	-
Lack of calculation	-	1
Non-compliance	1	1
Lost to follow-up	1	-
Sponsor decision	-	-
Technical reason	-	-
Lack of efficacy	17	23
Protocol deviation	1	-

## Period 2

Period 2 title	Maintenance Phase
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo/Placebo

### Arm description:

Participants who received placebo during the Induction Phase (from Cohorts 1 and 3) and achieved a CDAI-70 response at Week 14 will undergo a sham randomization into the Maintenance Phase. Placebo responders from induction will receive blinded maintenance treatment with an SC injection of placebo once every 4 weeks (q4w) from Week 16 to Week 64.

Arm type	Placebo
Investigational medicinal product name	matching Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

### Dosage and administration details:

placebo during the Induction Phase (from Cohorts 1 and 3) and achieved a CDAI-70 response at Week 14 will undergo a sham randomization into the Maintenance Phase. Placebo responders from induction will receive blinded maintenance treatment with an SC injection of placebo once every 4 weeks (q4w) from Week 16 to Week 64.

<b>Arm title</b>	Etrolizumab/Placebo
------------------	---------------------

### Arm description:

Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm received blinded maintenance treatment with an SC injection of placebo q4w from Week 16 to Week 64.

Arm type	Experimental
----------	--------------



Investigational medicinal product name	Etolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

**Dosage and administration details:**

received etolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy re-randomized into the Maintenance Phase. Etolizumab responders from induction who are re-randomized to this arm received blinded maintenance treatment with an SC injection of placebo q4w from Week 16 to Week 64.

<b>Arm title</b>	Etolizumab/Etolizumab 105mg
------------------	-----------------------------

**Arm description:**

Participants who received etolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy re-randomized into the Maintenance Phase. Etolizumab responders from induction who are re-randomized to this arm received blinded maintenance treatment with an SC injection of etolizumab (105 mg) q4w from Week 16 to Week 64.

Arm type	Experimental
Investigational medicinal product name	Etolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

**Dosage and administration details:**

Participants who received etolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy re-randomized into the Maintenance Phase. Etolizumab responders from induction who are re-randomized to this arm received blinded maintenance treatment with an SC injection of etolizumab (105 mg) q4w from Week 16 to Week 64.

<b>Number of subjects in period 2<sup>[1]</sup></b>	Placebo/Placebo	Etolizumab/Placebo	Etolizumab/Etolizumab 105mg
Started	53	217	217
Completed	41	175	165
Not completed	12	42	52
various reasons for non-completion	12	42	52

**Notes:**

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Induction and Maintenance Phases have mutually exclusive cohorts.

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo Cohort 1
Reporting group description: Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.	
Reporting group title	Etrolizumab 105mg Cohort 1
Reporting group description: Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.	
Reporting group title	Etrolizumab 210mg Cohort 1
Reporting group description: Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one SC injection of etrolizumab (210 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.	
Reporting group title	Etrolizumab 105mg Cohort 2
Reporting group description: Cohort 2 is enrolling participants after Cohort 1 and is considered a "feeder" cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.	
Reporting group title	Etrolizumab 210mg Cohort 2
Reporting group description: Cohort 2 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (210 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.	
Reporting group title	Placebo Cohort 3
Reporting group description: Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.	
Reporting group title	Etrolizumab 105mg Cohort 3
Reporting group description: Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.	
Reporting group title	Etrolizumab 210mg Cohort 3
Reporting group description: Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm received one SC injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.	

Reporting group values	Placebo Cohort 1	Etrolizumab 105mg Cohort 1	Etrolizumab 210mg Cohort 1
Number of subjects	59	120	121
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	57	116	118
From 65-84 years	2	4	3
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	36.5	38.9	38.6
standard deviation	± 12.7	± 13.1	± 13.4
Sex: Female, Male Units: Participants			
Female	31	57	68
Male	28	63	53
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	2	5	5
Not Hispanic or Latino	53	110	113
Unknown or Not Reported	4	5	3
Race/Ethnicity, Customized			
race			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	5	9	7
Black or African American	3	5	2
White	46	96	104
Other	5	10	8

Reporting group values	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2	Placebo Cohort 3
Number of subjects	176	174	97
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	169	166	93
From 65-84 years	7	8	4
85 years and over	0	0	0

Age Continuous Units: Years arithmetic mean standard deviation	38.4 ± 13.3	38.2 ± 13.2	37.1 ± 13.6
Sex: Female, Male Units: Participants			
Female	80	80	38
Male	96	94	59
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	7	8	15
Not Hispanic or Latino	160	154	75
Unknown or Not Reported	9	12	7
Race/Ethnicity, Customized			
race			
Units: Subjects			
American Indian or Alaska Native	0	0	1
Asian	8	14	0
Black or African American	1	5	6
White	153	141	81
Other	14	14	9

<b>Reporting group values</b>	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3	Total
Number of subjects	143	145	1035
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	137	141	997
From 65-84 years	6	4	38
85 years and over	0	0	0
Age Continuous Units: Years arithmetic mean standard deviation	38.3 ± 13.4	36.5 ± 13.1	-
Sex: Female, Male Units: Participants			
Female	69	69	492
Male	74	76	543
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	13	7	62
Not Hispanic or Latino	126	129	920
Unknown or Not Reported	4	9	53
Race/Ethnicity, Customized			
race			

Units: Subjects			
American Indian or Alaska Native	3	0	4
Asian	4	2	49
Black or African American	8	2	32
White	117	128	866
Other	11	13	84

## End points

### End points reporting groups

Reporting group title	Placebo Cohort 1
Reporting group description: Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.	
Reporting group title	Etrolizumab 105mg Cohort 1
Reporting group description: Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.	
Reporting group title	Etrolizumab 210mg Cohort 1
Reporting group description: Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one SC injection of etrolizumab (210 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.	
Reporting group title	Etrolizumab 105mg Cohort 2
Reporting group description: Cohort 2 is enrolling participants after Cohort 1 and is considered a "feeder" cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.	
Reporting group title	Etrolizumab 210mg Cohort 2
Reporting group description: Cohort 2 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (210 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.	
Reporting group title	Placebo Cohort 3
Reporting group description: Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.	
Reporting group title	Etrolizumab 105mg Cohort 3
Reporting group description: Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants also received one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.	
Reporting group title	Etrolizumab 210mg Cohort 3
Reporting group description: Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm received one SC injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.	
Reporting group title	Placebo/Placebo

Reporting group description:

Participants who received placebo during the Induction Phase (from Cohorts 1 and 3) and achieved a CDAI-70 response at Week 14 will undergo a sham randomization into the Maintenance Phase. Placebo responders from induction will receive blinded maintenance treatment with an SC injection of placebo once every 4 weeks (q4w) from Week 16 to Week 64.

Reporting group title	Etrolizumab/Placebo
-----------------------	---------------------

Reporting group description:

Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm received blinded maintenance treatment with an SC injection of placebo q4w from Week 16 to Week 64.

Reporting group title	Etrolizumab/Etrolizumab 105mg
-----------------------	-------------------------------

Reporting group description:

Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm received blinded maintenance treatment with an SC injection of etrolizumab (105 mg) q4w from Week 16 to Week 64.

Subject analysis set title	Maintenance Phase - Etrolizumab 105 mg/ Etrolizumab 105 mg
----------------------------	--

Subject analysis set type	Modified intention-to-treat
---------------------------	-----------------------------

Subject analysis set description:

Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of etrolizumab (105 mg) q4w from Week 16 to Week 64.

Subject analysis set title	Maintenance Phase - Etrolizumab 210 mg/ Etrolizumab 105 mg
----------------------------	--

Subject analysis set type	Modified intention-to-treat
---------------------------	-----------------------------

Subject analysis set description:

Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of etrolizumab (105 mg) q4w from Week 16 to Week 64.

Subject analysis set title	Etro 105mg Induction Only Cohort
----------------------------	----------------------------------

Subject analysis set type	Modified intention-to-treat
---------------------------	-----------------------------

Subject analysis set description:

Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8 and 12

Subject analysis set title	Etro 210mg Induction Only Cohort
----------------------------	----------------------------------

Subject analysis set type	Modified intention-to-treat
---------------------------	-----------------------------

Subject analysis set description:

Participants randomized to this arm will receive one SC injection of etrolizumab (210 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8 and 12

Subject analysis set title	Etro 105/ Placebo Induction and Maintenance Phase Cohort
----------------------------	--

Subject analysis set type	Modified intention-to-treat
---------------------------	-----------------------------

Subject analysis set description:

Participants who received etrolizumab 105 mg during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy that were re-randomized into the Maintenance Phase. Etrolizumab responders from induction who re re-randomized to this arm received blinded maintenance treatment with an SC injection of placebo q4w from Week 16 to Week 64

Subject analysis set title	Etro 210/ Placebo Induction and Maintenance Phase
----------------------------	---

Subject analysis set type	Modified intention-to-treat
---------------------------	-----------------------------

Subject analysis set description:

Participants who received etrolizumab 210 mg during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy that were re-randomized into the Maintenance Phase. Etrolizumab responders from induction who were re-randomized to this arm

received blinded maintenance treatment with an SC injection of placebo q4w from Week 16 to Week 64

Subject analysis set title	Etro 105/Etro 105 Induction and Maintenance Phase
Subject analysis set type	Modified intention-to-treat

Subject analysis set description:

Participants who received etrolizumab 105mg during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy that were re-randomized into the Maintenance Phase. Etrolizumab responders from induction who were re-randomized to this arm received blinded maintenance treatment with an SC injection of etrolizumab 105mg q4w from Week 16 to Week 64

Subject analysis set title	Etro 210/Etro 105 Induction and Maintenance Phase
Subject analysis set type	Modified intention-to-treat

Subject analysis set description:

Participants who received etrolizumab 210mg during the Induction Phase (from Cohorts 1-3) and achieved CDAI-70 response at Week 14 without the use of rescue therapy that were re-randomized into the Maintenance Phase. Etrolizumab responders from induction who were re-randomized to this arm received blinded maintenance treatment with an SC injection of etrolizumab 105mg q4w from Week 16 to Week 64

### **Primary: Induction Phase: Percentage of Participants with Clinical Remission at Week 14**

End point title	Induction Phase: Percentage of Participants with Clinical Remission at Week 14
-----------------	--

End point description:

Clinical remission is defined as liquid/soft stool frequency (SF) mean daily score less than or equal ( $\leq$ )3 and abdominal pain mean daily score  $\leq 1$ , with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit. Cohort 1 data represents 90% CI.

End point type	Primary
----------------	---------

End point timeframe:

Week 14

End point values	Placebo Cohort 1	Etrolizumab 105mg Cohort 1	Etrolizumab 210mg Cohort 1	Etrolizumab 105mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59	120	121	176
Units: Percentage of Participants				
number (confidence interval 95%)	11.9 (6.56 to 20.51)	20.00 (14.69 to 26.64)	27.3 (21.16 to 34.37)	29.5 (23.30 to 36.66)

End point values	Etrolizumab 210mg Cohort 2	Placebo Cohort 3	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	174	96	143	145
Units: Percentage of Participants				
number (confidence interval 95%)	29.3 (23.05 to 36.46)	29.2 (21.02 to 38.92)	30.1 (23.16 to 38.03)	33.1 (25.97 to 41.11)



## Statistical analyses

<b>Statistical analysis title</b>	Clinical Remission at Week 14
-----------------------------------	-------------------------------

Statistical analysis description:

Percentage of Participants with Clinical Remission at Week 14 3 presented

Comparison groups	Placebo Cohort 1 v Etrolizumab 105mg Cohort 1 v Etrolizumab 210mg Cohort 1 v Etrolizumab 105mg Cohort 2 v Etrolizumab 210mg Cohort 2 v Placebo Cohort 3 v Etrolizumab 105mg Cohort 3 v Etrolizumab 210mg Cohort 3
Number of subjects included in analysis	1034
Analysis specification	Pre-specified
Analysis type	superiority <sup>[1]</sup>
P-value	= 0.5235 <sup>[2]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	3.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.3
upper limit	15.27
Variability estimate	Standard deviation

Notes:

[1] - Formal results for Etrolizumab 210mg vs. Placebo for Cohort 3 are presented

[2] - P-values are presented for Cohort 3 only. The p-values adjusted for multiplicity are presented

### Primary: Induction Phase: Percentage of Participants with Endoscopic Improvement at Week 14

End point title	Induction Phase: Percentage of Participants with Endoscopic Improvement at Week 14
-----------------	--

End point description:

Endoscopic improvement is defined as 50 percent (%) reduction from baseline in Simplified Endoscopic Index for Crohn's Disease (SES-CD) score.

End point type	Primary
----------------	---------

End point timeframe:

Week 14

End point values	Placebo Cohort 1	Etrolizumab 105mg Cohort 1	Etrolizumab 210mg Cohort 1	Etrolizumab 105mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59	120	121	176
Units: Percentage				
number (confidence interval 95%)	3.4 (-1.74 to 8.52)	19.5 (12.37 to 26.64)	16.8 (10.11 to 23.50)	20.8 (14.81 to 26.86)

End point values	Etrolizumab 210mg Cohort 2	Placebo Cohort 3	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3
------------------	----------------------------	------------------	----------------------------	----------------------------

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	174	96	143	145
Units: Percentage				
number (confidence interval 95%)	22.2 (16.02 to 28.35)	21.6 (13.24 to 29.95)	26.2 (18.96 to 33.44)	27.4 (20.01 to 34.79)

## Statistical analyses

<b>Statistical analysis title</b>	Participants with Endoscopic Improvement Week 14
Statistical analysis description:	
Percentage of Participants with Endoscopic Improvement at Week 14	
Comparison groups	Placebo Cohort 1 v Etrolizumab 105mg Cohort 1 v Etrolizumab 210mg Cohort 1 v Etrolizumab 105mg Cohort 2 v Etrolizumab 210mg Cohort 2 v Placebo Cohort 3 v Etrolizumab 105mg Cohort 3 v Etrolizumab 210mg Cohort 3
Number of subjects included in analysis	1034
Analysis specification	Pre-specified
Analysis type	superiority <sup>[3]</sup>
P-value	= 0.317 <sup>[4]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	5.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.43
upper limit	17.05
Variability estimate	Standard deviation

Notes:

[3] - Formal results for Etrolizumab 210mg vs. Placebo for Cohort 3 are presented

[4] - Adjusted p-values are presented

## Primary: Maintenance Phase: Percentage of Participants with Clinical Remission at Week 66

End point title	Maintenance Phase: Percentage of Participants with Clinical Remission at Week 66
End point description:	
Clinical remission is defined as SF mean daily score $\leq 3$ and abdominal pain mean daily score $\leq 1$ , with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit. Maintenance phase participants were evaluated.	
End point type	Primary
End point timeframe:	
Baseline and Week 66	

End point values	Placebo/Placebo	Etrolizumab/Placebo	Etrolizumab/Etrolizumab 105mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	53	217	217	
Units: Percentage				
number (confidence interval 95%)	0 (0 to 0)	24.00 (18.77 to 30.06)	35.00 (28.99 to 41.58)	

## Statistical analyses

<b>Statistical analysis title</b>	Participants with Clinical Remission Week 66
Statistical analysis description:	
Percentage of Participants with Clinical Remission at Week 66	
Comparison groups	Placebo/Placebo v Etrolizumab/Placebo v Etrolizumab/Etrolizumab 105mg
Number of subjects included in analysis	487
Analysis specification	Pre-specified
Analysis type	superiority <sup>[5]</sup>
P-value	= 0.0088
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	11.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.7
upper limit	19.65
Variability estimate	Standard deviation

Notes:

[5] - Etrolizumab/Placebo vs. Etrolizumab/Etrolizumab 105mg.

## Primary: Maintenance Phase: Percentage of Participants with Endoscopic Improvement at Week 66

End point title	Maintenance Phase: Percentage of Participants with Endoscopic Improvement at Week 66
End point description:	
Endoscopic improvement is defined as 50% reduction from baseline in SES-CD score. Maintenance phase participants were evaluated.	
End point type	Primary
End point timeframe:	
Week 66	

End point values	Placebo/Placebo	Etrolizumab/Placebo	Etrolizumab/Etrolizumab 105mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	53	217	217	
Units: Percentage				
number (confidence interval 95%)	0 (0 to 0)	12.2 (7.71 to 16.69)	23.6 (17.90 to 29.29)	

## Statistical analyses

Statistical analysis title	Participants with Endoscopic Improvement Week 66
Statistical analysis description:	
Percentage of Participants with Endoscopic Improvement at Week 66	
Comparison groups	Placebo/Placebo v Etrolizumab/Placebo v Etrolizumab/Etrolizumab 105mg
Number of subjects included in analysis	487
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0026
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	11.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.11
upper limit	18.83
Variability estimate	Standard deviation

## Secondary: Induction Phase: Percentage of Participants with Clinical Remission at Week 6

End point title	Induction Phase: Percentage of Participants with Clinical Remission at Week 6
End point description:	
Clinical remission is defined as SF mean daily score $\leq 3$ and abdominal pain mean daily score $\leq 1$ , with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit.	
End point type	Secondary
End point timeframe:	
Week 6	

End point values	Placebo Cohort 1	Etrolizumab 105mg Cohort 1	Etrolizumab 210mg Cohort 1	Etrolizumab 105mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59	120	121	176
Units: Percentage				
number (confidence interval 95%)	5.1 (2.05 to 12.06)	15.0 (10.41 to 21.13)	24.8 (18.93 to 31.75)	20.5 (15.16 to 27.01)

End point values	Etrolizumab 210mg Cohort 2	Placebo Cohort 3	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	174	96	143	145
Units: Percentage				
number (confidence interval 95%)	21.3 (15.84 to 27.93)	20.8 (13.91 to 30.00)	23.8 (17.54 to 31.38)	23.4 (17.29 to 30.97)

## Statistical analyses

Statistical analysis title	Participants with Clinical Remission Week 6
Statistical analysis description:	
Percentage of Participants with Clinical Remission at Week 6	
Comparison groups	Placebo Cohort 1 v Etrolizumab 105mg Cohort 1 v Etrolizumab 210mg Cohort 1 v Etrolizumab 105mg Cohort 2 v Etrolizumab 210mg Cohort 2 v Placebo Cohort 3 v Etrolizumab 105mg Cohort 3 v Etrolizumab 210mg Cohort 3
Number of subjects included in analysis	1034
Analysis specification	Pre-specified
Analysis type	superiority <sup>[6]</sup>
P-value	= 0.7908 <sup>[7]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	2.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.78
upper limit	12.56
Variability estimate	Standard deviation

Notes:

[6] - Formal results for Etrolizumab 210mg vs. Placebo for Cohort 3 are presented

[7] - Adjusted p-values are presented

## Secondary: Induction Phase: Percentage of Participants with SES-CD Score ≤4 (≤2 for Ileal Participants), with No Segment Having a Subcategory Score Greater than (>)1, at Week 14

End point title	Induction Phase: Percentage of Participants with SES-CD Score ≤4 (≤2 for Ileal Participants), with No Segment Having a Subcategory Score Greater than (>)1, at Week 14
-----------------	--

End point description:

Endoscopic Remission is defined as SES-CD  $\leq 4$  ( $\leq 2$  for ileal patients), with no segment having a subcategory score  $>1$ . The Maintenance Cohorts are not included.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 14

End point values	Placebo Cohort 1	Etrolizumab 105mg Cohort 1	Etrolizumab 210mg Cohort 1	Etrolizumab 105mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59	120	121	176
Units: Percentage				
number (confidence interval 95%)	1.7 (-2.40 to 5.79)	13.8 (7.53 to 20.14)	8.3 (3.29 to 13.24)	9.9 (5.43 to 14.42)

End point values	Etrolizumab 210mg Cohort 2	Placebo Cohort 3	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	174	96	143	145
Units: Percentage				
number (confidence interval 95%)	12.3 (5.43 to 14.42)	8.7 (2.84 to 14.52)	10.2 (5.15 to 15.27)	15.3 (9.33 to 21.29)

## Statistical analyses

<b>Statistical analysis title</b>	Participants with SES-CD Score $\leq 4$ ER
-----------------------------------	--

Statistical analysis description:

Percentage of Participants with SES-CD Score  $\leq 4$  ( $\leq 2$  for Ileal Participants), with No Segment Having a Subcategory Score Greater than ( $>$ )1, at Week 14. ER-Endoscopic Remission

Comparison groups	Placebo Cohort 1 v Etrolizumab 105mg Cohort 1 v Etrolizumab 210mg Cohort 1 v Etrolizumab 105mg Cohort 2 v Etrolizumab 210mg Cohort 2 v Placebo Cohort 3 v Etrolizumab 105mg Cohort 3 v Etrolizumab 210mg Cohort 3
Number of subjects included in analysis	1034
Analysis specification	Pre-specified
Analysis type	superiority <sup>[8]</sup>
P-value	= 0.5235 <sup>[9]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	6.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.24
upper limit	15.16

Variability estimate	Standard deviation
Notes:	
[8] - Formal results for Etrolizumab 210mg vs. Placebo for Cohort 3 are presented	
[9] - Adjusted p-values are presented	
<b>Secondary: Induction Phase: Change from Baseline in Crohn's Disease-Patient-Reported Outcome Signs and Symptoms (CD-PRO/SS) Score at Week 14</b>	
End point title	Induction Phase: Change from Baseline in Crohn's Disease-Patient-Reported Outcome Signs and Symptoms (CD-PRO/SS) Score at Week 14
End point description:	
Change from Baseline in CD-PRO/SS Bowel Signs and Symptoms at Week 14. A score is calculated as the average across 4-7 days eDiary data within a 9 day window from visit, else the score is considered missing. Participants are included in the analysis if they have a baseline and at least one post-baseline score available. A lower CD-PRO score indicates a higher quality of life.	
End point type	Secondary
End point timeframe:	
Baseline and Week 14	

End point values	Placebo Cohort 1	Etrolizumab 105mg Cohort 1	Etrolizumab 210mg Cohort 1	Etrolizumab 105mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59	120	121	176
Units: Least Square Means				
least squares mean (standard error)	-07 (± 0.4)	-1.4 (± 0.3)	-1.6 (± 0.3)	-2.0 (± 0.2)

End point values	Etrolizumab 210mg Cohort 2	Placebo Cohort 3	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	174	96	143	145
Units: Least Square Means				
least squares mean (standard error)	-2.3 (± 0.2)	-1.9 (± 0.3)	-1.6 (± 0.2)	-1.9 (± 0.2)

## Statistical analyses

<b>Statistical analysis title</b>	Change from Baseline in CD-PRO/SS Bowel Domain
Statistical analysis description:	
Induction Phase: Change from Baseline in Crohn's Disease-Patient-Reported Outcome Signs and Symptoms (CD-PRO/SS) Score at Week 14	
Comparison groups	Placebo Cohort 1 v Etrolizumab 105mg Cohort 1 v Etrolizumab 210mg Cohort 1 v Etrolizumab 105mg Cohort 2 v Etrolizumab 210mg Cohort 2 v Placebo Cohort 3 v Etrolizumab 105mg Cohort 3 v Etrolizumab 210mg Cohort 3

Number of subjects included in analysis	1034
Analysis specification	Pre-specified
Analysis type	superiority <sup>[10]</sup>
P-value	= 1 <sup>[11]</sup>
Method	Mixed models analysis
Parameter estimate	Median difference (final values)
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.1
upper limit	0.5
Variability estimate	Standard deviation

Notes:

[10] - Formal results for Etrolizumab 210mg vs. Placebo for Cohort 3 are presented

[11] - Adjusted p-values are presented

### Secondary: Maintenance Phase: Percentage of Participants with Clinical Remission at Week 66, Among Those who Achieved Clinical Remission at Week 14

End point title	Maintenance Phase: Percentage of Participants with Clinical Remission at Week 66, Among Those who Achieved Clinical Remission at Week 14
-----------------	--

End point description:

Clinical remission is defined as SF mean daily score  $\leq 3$  and abdominal pain mean daily score  $\leq 1$ , with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit. Induction Phase Cohorts are not included

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 14 and 66

End point values	Placebo/Placebo	Etrolizumab/Placebo	Etrolizumab/Etrolizumab 105mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	53	97	108	
Units: Percentage				
number (confidence interval 95%)	0 (0 to 0)	39.2 (30.05 to 49.12)	56.5 (47.07 to 65.45)	

### Statistical analyses

Statistical analysis title	CR at Week 66 subjects achieved CR at Week 14
----------------------------	---

Statistical analysis description:

Percentage of Participants with Clinical Remission at Week 66, Among Those who Achieved Clinical Remission at Week 14

Comparison groups	Placebo/Placebo v Etrolizumab/Placebo v Etrolizumab/Etrolizumab 105mg
-------------------	---



Number of subjects included in analysis	258
Analysis specification	Pre-specified
Analysis type	superiority <sup>[12]</sup>
P-value	= 0.067 <sup>[13]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.52
upper limit	30.27
Variability estimate	Standard deviation

Notes:

[12] - Etrolizuab/Placebo vs. Etrolizumab/Etrolizumab. Only patients achieving Clinical Remission at Week 14 are included in the analysis

[13] - Adjusted p-values are presented

### Secondary: Maintenance Phase: Percentage of Participants with Corticosteroid-Free Clinical Remission at Week 66, Among Those who Were Receiving Corticosteroids at Baseline

End point title	Maintenance Phase: Percentage of Participants with Corticosteroid-Free Clinical Remission at Week 66, Among Those who Were Receiving Corticosteroids at Baseline
-----------------	--

End point description:

Clinical remission is defined as SF mean daily score  $\leq 3$  and abdominal pain mean daily score  $\leq 1$ , with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit.

Induction Phase Cohorts are not included

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 66

End point values	Placebo/Placebo	Etrolizumab/Placebo	Etrolizumab/Etrolizumab 105mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	53	217	217	
Units: Percentage				
number (confidence interval 95%)	0 (0 to 0)	11.0 (6.08 to 19.06)	29.0 (20.79 to 38.94)	

### Statistical analyses

Statistical analysis title	Participants with Corticosteroid-Free CR Week 66
----------------------------	--

Statistical analysis description:

Maintenance Phase: Percentage of Participants with Corticosteroid-Free Clinical Remission at Week 66, Among Those who Were Receiving Corticosteroids at Baseline

Comparison groups	Placebo/Placebo v Etrolizumab/Placebo v Etrolizumab/Etrolizumab 105mg
-------------------	---

Number of subjects included in analysis	487
Analysis specification	Pre-specified
Analysis type	superiority <sup>[14]</sup>
P-value	= 0.048 <sup>[15]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	18.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	11.07
upper limit	25.96
Variability estimate	Standard deviation

Notes:

[14] - Etrolizumab/Placebo vs. Etrolizumab/Etrolizumab 105mg. Only patients receiving oral corticosteroids at Baseline are included in the analysis

[15] - Adjusted p-values are presented

### Secondary: Maintenance Phase: Percentage of Participants with Endoscopic Improvement at Week 66 Among Participants who Achieved Endoscopic Improvement at Week 14

End point title	Maintenance Phase: Percentage of Participants with Endoscopic Improvement at Week 66 Among Participants who Achieved Endoscopic Improvement at Week 14
-----------------	--

End point description:

Endoscopic improvement is defined as 50% reduction from baseline in SES-CD score. Induction Phase Cohorts are not included

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 14 and 66

End point values	Placebo/Placebo	Etrolizumab/Placebo	Etrolizumab/Etrolizumab 105mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	53 <sup>[16]</sup>	58	72	
Units: Percentage				
number (confidence interval 95%)	0 (0 to 0)	25.3 (14.14 to 36.44)	37.5 (26.28 to 48.72)	

Notes:

[16] - Placebo group was not analysed

### Statistical analyses

Statistical analysis title	Subjects with Endoscopic Improvement Week 66
Statistical analysis description:	
	Etrolizumab/Placebo vs. Etrolizumab/Etrolizumab 105mg. Only patients achieving endoscopic Improvement at Week 14 are included in the analysis.
Comparison groups	Placebo/Placebo v Etrolizumab/Placebo v Etrolizumab/Etrolizumab 105mg

Number of subjects included in analysis	183
Analysis specification	Pre-specified
Analysis type	superiority <sup>[17]</sup>
P-value	= 0.121 <sup>[18]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	13.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.9
upper limit	29.94
Variability estimate	Standard deviation

Notes:

[17] - Etrolizumab/Placebo vs. Etrolizumab/Etrolizumab 105mg

[18] - Nominal p-value presented. No adjustment for multiplicity

### **Secondary: Maintenance Phase: Percentage of Participants with SES-CD Score ≤4 (≤2 for Ileal Participants), with No Segment Having a Subcategory Score >1, at Week 66**

End point title	Maintenance Phase: Percentage of Participants with SES-CD Score ≤4 (≤2 for Ileal Participants), with No Segment Having a Subcategory Score >1, at Week 66
-----------------	---

End point description:

Endoscopic Remission is defined as SES-CD ≤4 (≤2 for ileal participants), with no segment having a subcategory score >1.

ICEs are handled as follows: rescue therapy, withdrawal and deaths are imputed as non-responder.

Covid-19 ICEs and missing data are handled using multiple imputation.

Patients with partial segments available are handled as follows: segments missing at Baseline was not considered in the postbaseline

SES-CD total score calculation. Induction Phase Cohorts are not included

End point type	Secondary
----------------	-----------

End point timeframe:

Week 66

End point values	Placebo/Placebo	Etrolizumab/Placebo	Etrolizumab/Etrolizumab 105mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	53 <sup>[19]</sup>	217	217	
Units: Percentage				
number (confidence interval 95%)	0 (0 to 0)	5.9 (2.62 to 9.18)	12.1 (7.61 to 16.54)	

Notes:

[19] - Placebo cohort was not analysed

### **Statistical analyses**

<b>Statistical analysis title</b>	Participants with SES-CD Score ≤4
-----------------------------------	-----------------------------------

Statistical analysis description:

Maintenance Phase: Percentage of Participants with SES-CD Score ≤4 (≤2 for Ileal Participants), with No Segment Having a Subcategory Score >1, at Week 66

Comparison groups	Placebo/Placebo v Etrolizumab/Placebo v Etrolizumab/Etrolizumab 105mg
Number of subjects included in analysis	487
Analysis specification	Pre-specified
Analysis type	superiority <sup>[20]</sup>
P-value	= 0.048 <sup>[21]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	6.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.54
upper limit	11.93
Variability estimate	Standard deviation

Notes:

[20] - Etrolizumab/Placebo vs. Etrolizumab/Etrolizumab 105mg

[21] - Adjusted p-values are presented

## Secondary: Maintenance Phase: Percentage of Participants with Durable Clinical Remission

End point title	Maintenance Phase: Percentage of Participants with Durable Clinical Remission
-----------------	---

End point description:

Clinical remission is defined as SF mean daily score  $\leq 3$  and abdominal pain mean daily score  $\leq 1$ , with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit. Durable clinical remission was defined as clinical remission at  $\geq 4$  of the 6 in-clinic assessment visits conducted during the Maintenance Phase at Weeks 24, 28, 32, 44, 56, and 66. Induction Phase Cohorts are not included

End point type	Secondary
----------------	-----------

End point timeframe:

Week 14 up to Week 66 (assessed at Weeks 24, 28, 32, 44, 56, and 66)

End point values	Placebo/Placebo	Etrolizumab/Placebo	Etrolizumab/Etrolizumab 105mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	53 <sup>[22]</sup>	217	217	
Units: Percentage				
number (confidence interval 95%)	0 (0 to 0)	19.8 (15.06 to 25.62)	30.9 (25.11 to 37.31)	

Notes:

[22] - Placebo group was not analysed

## Statistical analyses

Statistical analysis title	Participants with Durable CR
----------------------------	------------------------------

Statistical analysis description:

Maintenance Phase: Percentage of Participants with Durable Clinical Remission (CR)

Comparison groups	Placebo/Placebo v Etrolizumab/Placebo v Etrolizumab/Etrolizumab 105mg
-------------------	---

Number of subjects included in analysis	487
Analysis specification	Pre-specified
Analysis type	superiority <sup>[23]</sup>
P-value	= 0.0677 <sup>[24]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	11.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.04
upper limit	19.24
Variability estimate	Standard deviation

Notes:

[23] - Etrolizumab/Placebo vs. Etrolizumab

[24] - Adjusted p-values are presented

### Secondary: Maintenance Phase: Percentage of Participants with Corticosteroid-Free Clinical Remission for at Least 24 Weeks at Week 66, Among Those who Were Receiving Corticosteroids at Baseline

End point title	Maintenance Phase: Percentage of Participants with Corticosteroid-Free Clinical Remission for at Least 24 Weeks at Week 66, Among Those who Were Receiving Corticosteroids at Baseline
-----------------	--

End point description:

Clinical remission is defined as SF mean daily score  $\leq 3$  and abdominal pain mean daily score  $\leq 1$ , with no worsening in either subscore compared to baseline, averaged over the 7 days prior to visit.

Percentage of participants with clinical remission who will be off corticosteroids for at least 24 weeks prior to Week 66 will be reported.

Induction Phase COHORTS are not included

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and from Week 14 up to Week 66

End point values	Placebo/Placebo	Etrolizumab/Placebo	Etrolizumab/Etrolizumab 105mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	53 <sup>[25]</sup>	91	93	
Units: Percentage				
number (confidence interval 95%)	0 (0 to 0)	9.9 (5.29 to 17.74)	25.8 (18.00 to 35.53)	

Notes:

[25] - Placebo group was not analysed

### Statistical analyses

Statistical analysis title	Participants with Corticosteroid-Free CR Week 66
Statistical analysis description:	
	Maintenance Phase: Percentage of Participants with Corticosteroid-Free Clinical Remission for at Least 24 Weeks at Week 66, Among Those who Were Receiving Corticosteroids at Baseline
Comparison groups	Placebo/Placebo v Etrolizumab/Placebo v

	Etrolizumab/Etrolizumab 105mg
Number of subjects included in analysis	237
Analysis specification	Pre-specified
Analysis type	superiority <sup>[26]</sup>
P-value	= 0.0035 <sup>[27]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	16.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.96
upper limit	23.31
Variability estimate	Standard deviation

Notes:

[26] - Etrolizumab/Placebo vs. Etrolizumab/Etrolizumab 105mg

[27] - Nominal p-values are presented. No adjustment for multiplicity

## Secondary: Maintenance Phase: Change from Baseline in CD-PRO/SS Score at Week 66

End point title	Maintenance Phase: Change from Baseline in CD-PRO/SS Score at Week 66
End point description:	
Change from Baseline in CD-PRO/SS Bowel and Abdominal Signs and Symptoms at Week 66	
End point type	Secondary
End point timeframe:	
Baseline and Week 66	

End point values	Placebo/Placebo	Etrolizumab/Placebo	Etrolizumab/Etrolizumab 105mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	53 <sup>[28]</sup>	180	180	
Units: Least Square Means				
arithmetic mean (standard error)				
Bowel	0 (± 0)	-1.7 (± 0.3)	-2.0 (± 0.3)	
Abdominal	0 (± 0)	-1.4 (± 0.2)	-1.7 (± 0.2)	

Notes:

[28] - Placebo group was not analysed

## Statistical analyses

Statistical analysis title	Change from Baseline in CD-PRO/SS Score Week 66
Statistical analysis description:	
Maintenance Phase: Change from Baseline in CD-PRO/SS Score at Week 66	
Comparison groups	Placebo/Placebo v Etrolizumab/Placebo v Etrolizumab/Etrolizumab 105mg

Number of subjects included in analysis	413
Analysis specification	Pre-specified
Analysis type	superiority <sup>[29]</sup>
P-value	= 0.4009 <sup>[30]</sup>
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1
upper limit	0.4
Variability estimate	Standard deviation

Notes:

[29] - Etrolizumab/Placebo vs. Etrolizumab/Etrolizumab 105mg. Only patients with Baseline and at least one post-baseline CD-PRO/SS value are included in the analysis

[30] - Adjusted p-values are presented. Abdominal domain results are as follows: p-value=0.4009, difference=-0.3 [-0.9 , 0.4]

### **Secondary: Overall Number of Participants who Experienced at Least One Adverse Event by Severity, According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)**

End point title	Overall Number of Participants who Experienced at Least One Adverse Event by Severity, According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)
-----------------	--

End point description:

Investigator text for AEs is coded using MedDRA version 24.0.

For participants counts, multiple occurrences of AEs in the same category for an individual are counted only once. For event counts, multiple occurrences of AEs in the same category for an individual are counted separately. Severity Grades from 1 to 5.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline up to Week 78

<b>End point values</b>	Placebo Cohort 1	Placebo/Placebo	Etrolizumab 105mg Cohort 1	Etrolizumab/Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59 <sup>[31]</sup>	53 <sup>[32]</sup>	120 <sup>[33]</sup>	217 <sup>[34]</sup>
Units: Number of Participants				
number (not applicable)	50	42	83	190

Notes:

[31] - data evaluable participants are included in each Grade group

[32] - data evaluable participants are included in each Grade group

[33] - data evaluable participants are included in each Grade group

[34] - data evaluable participants are included in each Grade group

<b>End point values</b>	Etrolizumab 210mg Cohort 1	Etrolizumab/Etrolizumab 105mg	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	121 <sup>[35]</sup>	217 <sup>[36]</sup>	176 <sup>[37]</sup>	174 <sup>[38]</sup>

Units: Number of Participants				
number (not applicable)	82	189	120	115

Notes:

[35] - data evaluable participants are included in each Grade group

[36] - data evaluable participants are included in each Grade group

[37] - data evaluable participants are included in each Grade group

[38] - data evaluable participants are included in each Grade group

End point values	Placebo Cohort 3	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	96 <sup>[39]</sup>	143 <sup>[40]</sup>	145 <sup>[41]</sup>	
Units: Number of Participants				
number (not applicable)	51	95	85	

Notes:

[39] - data evaluable participants are included in each Grade group

[40] - data evaluable participants are included in each Grade group

[41] - data evaluable participants are included in each Grade group

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Number of Participants with Adverse Events Leading to Study Drug Discontinuation

End point title	Overall Number of Participants with Adverse Events Leading to Study Drug Discontinuation
End point description:	Number of participants who discontinued the study due to the adverse events is reported.
End point type	Secondary
End point timeframe:	From Baseline up to Week 78

End point values	Placebo Cohort 1	Placebo/Placebo 0	Etrolizumab 105mg Cohort 1	Etrolizumab/Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59 <sup>[42]</sup>	53 <sup>[43]</sup>	120 <sup>[44]</sup>	217 <sup>[45]</sup>
Units: Number of Participants				
number (not applicable)	2	1	4	1

Notes:

[42] - data evaluable participants are included in each Grade group

[43] - data evaluable participants are included in each Grade group

[44] - data evaluable participants are included in each Grade group

[45] - data evaluable participants are included in each Grade group

End point values	Etrolizumab 210mg Cohort 1	Etrolizumab/Etrolizumab 105mg	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	121 <sup>[46]</sup>	217 <sup>[47]</sup>	176 <sup>[48]</sup>	174 <sup>[49]</sup>



Units: Number of Participants				
number (not applicable)	1	3	2	5

Notes:

[46] - data evaluable participants are included in each Grade group

[47] - data evaluable participants are included in each Grade group

[48] - data evaluable participants are included in each Grade group

[49] - data evaluable participants are included in each Grade group

End point values	Placebo Cohort 3	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	96 <sup>[50]</sup>	143 <sup>[51]</sup>	145 <sup>[52]</sup>	
Units: Number of Participants				
number (not applicable)	2	0	0	

Notes:

[50] - data evaluable participants are included in each Grade group

[51] - data evaluable participants are included in each Grade group

[52] - data evaluable participants are included in each Grade group

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Number of Participants who Experienced at Least One Infection-Related Adverse Event by Severity, According to NCI-CTCAE v4.0

End point title	Overall Number of Participants who Experienced at Least One Infection-Related Adverse Event by Severity, According to NCI-CTCAE v4.0
-----------------	--

End point description:

Participants who Experienced at Least One Infection-Related Adverse Event by Severity, According to NCI-CTCAE v4.0 are reported

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline up to Week 78

End point values	Placebo Cohort 1	Placebo/Placebo	Etrolizumab 105mg Cohort 1	Etrolizumab/Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59 <sup>[53]</sup>	53 <sup>[54]</sup>	120 <sup>[55]</sup>	217 <sup>[56]</sup>
Units: Number of Participants				
number (not applicable)				
Grade 1	8	9	10	44
Grade 2	8	11	17	65
Grade 3	1	2	2	11
Grade 4	0	0	1	1
Grade 5	0	0	0	0

Notes:

[53] - data evaluable participants are included in each Grade group

[54] - data evaluable participants are included in each Grade group

[55] - data evaluable participants are included in each Grade group

[56] - data evaluable participants are included in each Grade group

End point values	Etrolizumab 210mg Cohort 1	Etrolizumab/Etr olizumab 105mg	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	121 <sup>[57]</sup>	217 <sup>[58]</sup>	176 <sup>[59]</sup>	174 <sup>[60]</sup>
Units: Number of Participants				
number (not applicable)				
Grade 1	16	42	38	21
Grade 2	24	53	23	20
Grade 3	2	10	5	8
Grade 4	0	0	0	1
Grade 5	0	1	0	0

Notes:

[57] - data evaluable participants are included in each Grade group

[58] - data evaluable participants are included in each Grade group

[59] - data evaluable participants are included in each Grade group

[60] - data evaluable participants are included in each Grade group

End point values	Placebo Cohort 3	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	96 <sup>[61]</sup>	143 <sup>[62]</sup>	145 <sup>[63]</sup>	
Units: Number of Participants				
number (not applicable)				
Grade 1	8	25	21	
Grade 2	7	12	20	
Grade 3	1	2	1	
Grade 4	0	1	0	
Grade 5	0	0	0	

Notes:

[61] - data evaluable participants are included in each Grade group

[62] - data evaluable participants are included in each Grade group

[63] - data evaluable participants are included in each Grade group

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Number of Participants who Experienced at Least One Infection-Related Serious Adverse Event

End point title	Overall Number of Participants who Experienced at Least One Infection-Related Serious Adverse Event
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline up to Week 78

End point values	Placebo Cohort 1	Placebo/Placebo	Etrolizumab 105mg Cohort 1	Etrolizumab/Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59 <sup>[64]</sup>	53 <sup>[65]</sup>	120 <sup>[66]</sup>	217 <sup>[67]</sup>
Units: Number of Participants				
number (not applicable)	2	1	4	13

Notes:

[64] - data evaluable participants are included in each Grade group

[65] - data evaluable participants are included in each Grade group

[66] - data evaluable participants are included in each Grade group

[67] - data evaluable participants are included in each Grade group

End point values	Etrolizumab 210mg Cohort 1	Etrolizumab/Etrolizumab 105mg	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	121 <sup>[68]</sup>	217 <sup>[69]</sup>	176 <sup>[70]</sup>	174 <sup>[71]</sup>
Units: Number of Participants				
number (not applicable)	1	12	2	5

Notes:

[68] - data evaluable participants are included in each Grade group

[69] - data evaluable participants are included in each Grade group

[70] - data evaluable participants are included in each Grade group

[71] - data evaluable participants are included in each Grade group

End point values	Placebo Cohort 3	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	96 <sup>[72]</sup>	143 <sup>[73]</sup>	145 <sup>[74]</sup>	
Units: Number of Participants				
number (not applicable)	1	2	2	

Notes:

[72] - data evaluable participants are included in each Grade group

[73] - data evaluable participants are included in each Grade group

[74] - data evaluable participants are included in each Grade group

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Number of Participants who Experienced at Least One Injection-Site Reaction by Severity, According to NCI-CTCAE v4.0

End point title	Overall Number of Participants who Experienced at Least One Injection-Site Reaction by Severity, According to NCI-CTCAE v4.0
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point values	Placebo Cohort 1	Placebo/Placebo	Etrolizumab 105mg Cohort 1	Etrolizumab/Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59 <sup>[75]</sup>	53 <sup>[76]</sup>	120 <sup>[77]</sup>	217 <sup>[78]</sup>
Units: Number of Participants				
number (not applicable)				
Grade 1	4	3	7	18
Grade 2	0	0	0	0
Grade 3	0	0	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0

Notes:

[75] - data evaluable participants are included in each Grade group

[76] - data evaluable participants are included in each Grade group

[77] - data evaluable participants are included in each Grade group

[78] - data evaluable participants are included in each Grade group

End point values	Etrolizumab 210mg Cohort 1	Etrolizumab/Etrolizumab 105mg	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	121 <sup>[79]</sup>	217 <sup>[80]</sup>	176 <sup>[81]</sup>	174 <sup>[82]</sup>
Units: Number of Participants				
number (not applicable)				
Grade 1	3	8	10	8
Grade 2	1	1	0	1
Grade 3	0	0	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0

Notes:

[79] - data evaluable participants are included in each Grade group

[80] - data evaluable participants are included in each Grade group

[81] - data evaluable participants are included in each Grade group

[82] - data evaluable participants are included in each Grade group

End point values	Placebo Cohort 3	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	96 <sup>[83]</sup>	143 <sup>[84]</sup>	145 <sup>[85]</sup>	
Units: Number of Participants				
number (not applicable)				
Grade 1	1	10	6	
Grade 2	0	1	0	
Grade 3	0	0	0	
Grade 4	0	0	0	
Grade 5	0	0	0	

Notes:

[83] - data evaluable participants are included in each Grade group

[84] - data evaluable participants are included in each Grade group

[85] - data evaluable participants are included in each Grade group

## Statistical analyses

No statistical analyses for this end point

### Secondary: Overall Number of Participants who Experienced at Least One Hypersensitivity Reaction by Severity, According to NCI-CTCAE v4.0

End point title	Overall Number of Participants who Experienced at Least One Hypersensitivity Reaction by Severity, According to NCI-CTCAE v4.0
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline up to Week 78

End point values	Placebo Cohort 1	Placebo/Placebo	Etrolizumab 105mg Cohort 1	Etrolizumab/Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59 <sup>[86]</sup>	53 <sup>[87]</sup>	120 <sup>[88]</sup>	217 <sup>[89]</sup>
Units: Number of Participants				
number (not applicable)				
Grade 1	0	0	0	0
Grade 2	2	0	1	0
Grade 3	0	0	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0

Notes:

[86] - data evaluable participants are included in each Grade group

[87] - data evaluable participants are included in each Grade group

[88] - data evaluable participants are included in each Grade group

[89] - data evaluable participants are included in each Grade group

End point values	Etrolizumab 210mg Cohort 1	Etrolizumab/Etrolizumab 105mg	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	121 <sup>[90]</sup>	217 <sup>[91]</sup>	176 <sup>[92]</sup>	174 <sup>[93]</sup>
Units: Number of Participants				
number (not applicable)				
Grade 1	0	0	0	0
Grade 2	1	0	0	0
Grade 3	0	0	0	0
Grade 4	0	0	0	0

Grade 5	0	0	0	0
---------	---	---	---	---

Notes:

[90] - data evaluable participants are included in each Grade group

[91] - data evaluable participants are included in each Grade group

[92] - data evaluable participants are included in each Grade group

[93] - data evaluable participants are included in each Grade group

End point values	Placebo Cohort 3	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	96 <sup>[94]</sup>	143 <sup>[95]</sup>	145 <sup>[96]</sup>	
Units: Number of Participants				
number (not applicable)				
Grade 1	0	0	0	
Grade 2	0	0	0	
Grade 3	0	0	0	
Grade 4	0	0	0	
Grade 5	0	0	0	

Notes:

[94] - data evaluable participants are included in each Grade group

[95] - data evaluable participants are included in each Grade group

[96] - data evaluable participants are included in each Grade group

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Number of Participants who Develop Malignancies

End point title	Overall Number of Participants who Develop Malignancies
End point description:	Participants with malignancies are reported.
End point type	Secondary
End point timeframe:	From Baseline up to Week 78

End point values	Placebo Cohort 1	Placebo/Placebo o	Etrolizumab 105mg Cohort 1	Etrolizumab/Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	59 <sup>[97]</sup>	53 <sup>[98]</sup>	120 <sup>[99]</sup>	217 <sup>[100]</sup>
Units: Number of Participants				
number (not applicable)	0	0	1	2

Notes:

[97] - data evaluable participants are included in each Grade group

[98] - data evaluable participants are included in each Grade group

[99] - data evaluable participants are included in each Grade group

[100] - data evaluable participants are included in each Grade group

End point values	Etrolizumab 210mg Cohort	Etrolizumab/Etrolizumab	Etrolizumab 105mg Cohort	Etrolizumab 210mg Cohort
------------------	-----------------------------	-------------------------	-----------------------------	-----------------------------

	1	105mg	2	2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	121 <sup>[101]</sup>	217 <sup>[102]</sup>	176 <sup>[103]</sup>	174 <sup>[104]</sup>
Units: Number of Participants				
number (not applicable)	1	1	0	1

Notes:

[101] - data evaluable participants are included in each Grade group

[102] - data evaluable participants are included in each Grade group

[103] - data evaluable participants are included in each Grade group

[104] - data evaluable participants are included in each Grade group

End point values	Placebo Cohort 3	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	96 <sup>[105]</sup>	143 <sup>[106]</sup>	145 <sup>[107]</sup>	
Units: Number of Participants				
number (not applicable)	0	0	0	

Notes:

[105] - data evaluable participants are included in each Grade group

[106] - data evaluable participants are included in each Grade group

[107] - data evaluable participants are included in each Grade group

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Etrolizumab

End point title	Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Etrolizumab
-----------------	---

End point description:

Participants who received at least one dose of study treatment and had at least one baseline or post-baseline ATA result. Induction: treatment groups were pooled across cohorts 1-3. Maintenance: treatment group is stratified by induction dose

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Pre-dose (Hour 0) on Weeks 4, 14, 24, 32, 44, 66 or early termination, 12 weeks after last dose (up to Week 78)

End point values	Etro 105mg Induction Only Cohort	Etro 210mg Induction Only Cohort	Etro 105/ Placebo Induction and Maintenance Phase Cohort	Etro 210/ Placebo Induction and Maintenance Phase
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	22 <sup>[108]</sup>	223 <sup>[109]</sup>	108 <sup>[110]</sup>	109 <sup>[111]</sup>
Units: Percentage of Participants				
number (not applicable)				
Baseline with positive ADA	4.1	2.8	2.8	5.6
Treatment emergent ADA	23	22.7	23.1	33.1

Notes:

[108] - Data evaluable participants are included in each group

[109] - Data evaluable participants are included in each group

[110] - Data evaluable participants are included in each group

[111] - Data evaluable participants are included in each group

End point values	Etro 105/Etro 105 Induction and Maintenance Phase	Etro 210/Etro 105 Induction and Maintenance Phase		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	109 <sup>[112]</sup>	108 <sup>[113]</sup>		
Units: Percentage of Participants				
number (not applicable)				
Baseline with positive ADA	2.8	0		
Treatment emergent ADA	33.9	21.3		

Notes:

[112] - Data evaluable participants are included in each group

[113] - Data evaluable participants are included in each group

## Statistical analyses

No statistical analyses for this end point

## Secondary: Observed Trough Serum Concentration (Ctrough) of Etrolizumab

End point title	Observed Trough Serum Concentration (Ctrough) of Etrolizumab <sup>[114]</sup>
End point description:	Serum etrolizumab trough concentration
End point type	Secondary
End point timeframe:	Induction Phase at Weeks 10 and 14, Maintenance Phase at Weeks 16, 24, 28, 32, 44, and 66

Notes:

[114] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Data for this endpoint was provided only for those arms which were planned to be reported.

End point values	Etrolizumab 105mg Cohort 1	Etrolizumab 210mg Cohort 1	Etrolizumab 105mg Cohort 2	Etrolizumab 210mg Cohort 2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	117 <sup>[115]</sup>	121 <sup>[116]</sup>	175 <sup>[117]</sup>	172 <sup>[118]</sup>
Units: microgram/mL				
arithmetic mean (standard deviation)				
Week 10	9.39 (± 4.59)	25.1 (± 11.6)	10.3 (± 5.07)	25.7 (± 11.9)
Week 14	10.2 (± 5.27)	23.2 (± 10.6)	11.0 (± 5.04)	24.1 (± 11.4)
Week 16	0 (± 0)	0 (± 0)	0 (± 0)	0 (± 0)
Week 24	0 (± 0)	0 (± 0)	0 (± 0)	0 (± 0)
Week 28	0 (± 0)	0 (± 0)	0 (± 0)	0 (± 0)
Week 32	0 (± 0)	0 (± 0)	0 (± 0)	00 (± 0)
Week 44	0 (± 0)	0 (± 0)	0 (± 0)	0 (± 0)
Week 66	0 (± 0)	0 (± 0)	0 (± 0)	0 (± 0)



Notes:

[115] - Data evaluable participants are included in each cohort

[116] - Data evaluable participants are included in each cohort

[117] - Data evaluable participants are included in each cohort

[118] - Data evaluable participants are included in each cohort

<b>End point values</b>	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3	Maintenance Phase - Etrolizumab 105 mg/ Etrolizumab 105 mg	Maintenance Phase - Etrolizumab 210 mg/ Etrolizumab 105 mg
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	138 <sup>[119]</sup>	141 <sup>[120]</sup>	109 <sup>[121]</sup>	108 <sup>[122]</sup>
Units: microgram/mL				
arithmetic mean (standard deviation)				
Week 10	9.78 (± 4.63)	25.5 (± 11.0)	0 (± 0)	0 (± 0)
Week 14	10.8 (± 5.43)	24.6 (± 9.53)	0 (± 0)	0 (± 0)
Week 16	0 (± 0)	0 (± 0)	6.15 (± 4.20)	14.8 (± 10.5)
Week 24	0 (± 0)	0 (± 0)	6.58 (± 4.59)	8.20 (± 6.34)
Week 28	0 (± 0)	0 (± 0)	7.29 (± 8.45)	8.07 (± 5.81)
Week 32	0 (± 0)	0 (± 0)	7.13 (± 9.76)	7.89 (± 5.96)
Week 44	0 (± 0)	0 (± 0)	6.68 (± 3.75)	8.31 (± 6.68)
Week 66	0 (± 0)	0 (± 0)	11.7 (± 5.82)	12.2 (± 6.44)

Notes:

[119] - Data evaluable participants are included in each cohort

[120] - Data evaluable participants are included in each cohort

[121] - Data evaluable participants are included in each cohort

[122] - Data evaluable participants are included in each cohort

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From Baseline to Week 78

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MeDRA version 24.0
-----------------	--------------------

Dictionary version	24.0
--------------------	------

### Reporting groups

Reporting group title	Placebo Cohort 1
-----------------------	------------------

Reporting group description:

Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.

Reporting group title	Etrolizumab 105mg Cohort 1
-----------------------	----------------------------

Reporting group description:

Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Etrolizumab 105mg Cohort 2
-----------------------	----------------------------

Reporting group description:

Cohort 2 is enrolling participants after Cohort 1 and is considered a "feeder" cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Etrolizumab 210mg Cohort 1
-----------------------	----------------------------

Reporting group description:

Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one subcutaneous (SC) injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Etrolizumab 210mg Cohort 2
-----------------------	----------------------------

Reporting group description:

Cohort 2 is enrolling participants after Cohort 1 and is considered a "feeder" cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking for the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Placebo/Placebo
-----------------------	-----------------

Reporting group description:

Participants who received placebo during the Induction Phase (from Cohorts 1 and 3) and achieved a CDAI-70 response at Week 14 will undergo a sham randomization into the Maintenance Phase. Placebo responders from induction will receive blinded maintenance treatment with an SC injection of placebo once every 4 weeks (q4w) from Week 16 to Week 64.

Reporting group title	Etrolizumab 105mg Cohort 3
-----------------------	----------------------------

Reporting group description:

Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.

Reporting group title	Etrolizumab 210mg Cohort 3
Reporting group description:	
Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.	
Reporting group title	Placebo Cohort 3
Reporting group description:	
Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.	
Reporting group title	Etrolizumab/Etrolizumab 105mg
Reporting group description:	
Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of etrolizumab (105 mg) q4w from Week 16 to Week 64.	
Reporting group title	Etrolizumab/Placebo
Reporting group description:	
Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of placebo q4w from Week 16 to Week 64	

<b>Serious adverse events</b>	Placebo Cohort 1	Etrolizumab 105mg Cohort 1	Etrolizumab 105mg Cohort 2
Total subjects affected by serious adverse events			
subjects affected / exposed	8 / 59 (13.56%)	20 / 120 (16.67%)	18 / 176 (10.23%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma pancreas			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral embolism			

subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Removal of foreign body from gastrointestinal tract			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Granuloma			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Female genital tract fistula			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic pain			

subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax spontaneous			
subjects affected / exposed	0 / 59 (0.00%)	1 / 120 (0.83%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	1 / 59 (1.69%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatinine increased			
subjects affected / exposed	0 / 59 (0.00%)	1 / 120 (0.83%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver function test abnormal			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Gastrointestinal anastomotic leak			
subjects affected / exposed	0 / 59 (0.00%)	1 / 120 (0.83%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural intestinal perforation			

subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thermal burn			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral gas embolism			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tremor			
subjects affected / exposed	0 / 59 (0.00%)	1 / 120 (0.83%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 59 (1.69%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			

Acute vestibular syndrome subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertigo positional subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders Optic neuropathy subjects affected / exposed	0 / 59 (0.00%)	1 / 120 (0.83%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders Abdominal pain subjects affected / exposed	1 / 59 (1.69%)	0 / 120 (0.00%)	2 / 176 (1.14%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Crohn's disease subjects affected / exposed	6 / 59 (10.17%)	12 / 120 (10.00%)	5 / 176 (2.84%)
occurrences causally related to treatment / all	0 / 9	0 / 12	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Colitis			
subjects affected / exposed	0 / 59 (0.00%)	1 / 120 (0.83%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocutaneous fistula			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovesical fistula			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer haemorrhage			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileal stenosis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 59 (0.00%)	1 / 120 (0.83%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			



subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal fistula			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mechanical ileus			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 59 (0.00%)	1 / 120 (0.83%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal perforation			

subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Acute febrile neutrophilic dermatosis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema nodosum			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Excessive granulation tissue			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scar pain			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Chronic kidney disease			
subjects affected / exposed	0 / 59 (0.00%)	1 / 120 (0.83%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Nephrolithiasis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			
subjects affected / exposed	0 / 59 (0.00%)	1 / 120 (0.83%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 59 (1.69%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myositis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal abscess			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Abdominal wall abscess			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess intestinal			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asymptomatic COVID-19			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 59 (0.00%)	1 / 120 (0.83%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			

subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	1 / 59 (1.69%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis listeria			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pilonidal cyst			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			

subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal abscess			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 59 (0.00%)	1 / 120 (0.83%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	1 / 176 (0.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrolyte imbalance			

subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 59 (0.00%)	0 / 120 (0.00%)	0 / 176 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Etrolizumab 210mg Cohort 1	Etrolizumab 210mg Cohort 2	Placebo/Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	12 / 121 (9.92%)	20 / 174 (11.49%)	9 / 53 (16.98%)
number of deaths (all causes)	0	1	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma pancreas			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral embolism			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Removal of foreign body from gastrointestinal tract			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			

subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Granuloma			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Female genital tract fistula			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic pain			
subjects affected / exposed	1 / 121 (0.83%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax spontaneous			



subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatinine increased			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver function test abnormal			
subjects affected / exposed	1 / 121 (0.83%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Gastrointestinal anastomotic leak			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural intestinal perforation			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thermal burn			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Nervous system disorders			
Headache			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral gas embolism			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tremor			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 121 (0.83%)	0 / 174 (0.00%)	1 / 53 (1.89%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Acute vestibular syndrome			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertigo positional			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Optic neuropathy			

subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	2 / 121 (1.65%)	2 / 174 (1.15%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Crohn's disease			
subjects affected / exposed	7 / 121 (5.79%)	10 / 174 (5.75%)	4 / 53 (7.55%)
occurrences causally related to treatment / all	0 / 7	0 / 11	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocutaneous fistula			

subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovesical fistula			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer haemorrhage			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 53 (1.89%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileal stenosis			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal fistula			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			

subjects affected / exposed	0 / 121 (0.00%)	2 / 174 (1.15%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 53 (1.89%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mechanical ileus			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctitis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal perforation			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 53 (1.89%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholelithiasis			

subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Acute febrile neutrophilic dermatosis			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema nodosum			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Excessive granulation tissue			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scar pain			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Chronic kidney disease			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			

subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myositis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal abscess			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall abscess			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess intestinal			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Anal abscess			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asymptomatic COVID-19			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	1 / 121 (0.83%)	1 / 174 (0.57%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			



subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis listeria			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pilonidal cyst			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	1 / 53 (1.89%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal abscess			
subjects affected / exposed	1 / 121 (0.83%)	2 / 174 (1.15%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			

subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrolyte imbalance			
subjects affected / exposed	0 / 121 (0.00%)	0 / 174 (0.00%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	0 / 53 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Etrolizumab 105mg	Etrolizumab 210mg	Placebo Cohort 3
-------------------------------	-------------------	-------------------	------------------

	Cohort 3	Cohort 3	
Total subjects affected by serious adverse events			
subjects affected / exposed	12 / 143 (8.39%)	8 / 145 (5.52%)	8 / 96 (8.33%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma pancreas			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral embolism			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Removal of foreign body from gastrointestinal tract			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Granuloma			

subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Female genital tract fistula			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic pain			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax spontaneous			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatinine increased			

subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver function test abnormal			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Gastrointestinal anastomotic leak			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural intestinal perforation			
subjects affected / exposed	1 / 143 (0.70%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thermal burn			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral gas embolism			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Tremor			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 143 (1.40%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	1 / 143 (0.70%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Acute vestibular syndrome			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertigo positional			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Optic neuropathy			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 143 (0.00%)	2 / 145 (1.38%)	1 / 96 (1.04%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Crohn's disease			

subjects affected / exposed	7 / 143 (4.90%)	5 / 145 (3.45%)	3 / 96 (3.13%)
occurrences causally related to treatment / all	0 / 8	0 / 5	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocutaneous fistula			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovesical fistula			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer haemorrhage			

subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	1 / 96 (1.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileal stenosis			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal fistula			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mechanical ileus			



subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctitis			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 143 (0.00%)	1 / 145 (0.69%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal perforation			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Acute febrile neutrophilic dermatosis			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema nodosum			

subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Excessive granulation tissue			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scar pain			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Chronic kidney disease			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	1 / 96 (1.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Fistula			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myositis			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal abscess			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	1 / 96 (1.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall abscess			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess intestinal			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	1 / 143 (0.70%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	1 / 143 (0.70%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asymptomatic COVID-19			

subjects affected / exposed	0 / 143 (0.00%)	1 / 145 (0.69%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			

subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis listeria			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pilonidal cyst			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 143 (0.00%)	1 / 145 (0.69%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal abscess			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	1 / 143 (0.70%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			

subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrolyte imbalance			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	1 / 96 (1.04%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 143 (0.00%)	0 / 145 (0.00%)	0 / 96 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Etrolizumab/Etrolizumab 105mg	Etrolizumab/Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	30 / 217 (13.82%)	33 / 217 (15.21%)	
number of deaths (all causes)	1	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma pancreas			

subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral embolism			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Removal of foreign body from gastrointestinal tract			
subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Granuloma			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Drug hypersensitivity			

subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Female genital tract fistula			
subjects affected / exposed	0 / 217 (0.00%)	2 / 217 (0.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic pain			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax spontaneous			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Blood creatinine increased			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test abnormal			



subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Injury, poisoning and procedural complications</b>			
Gastrointestinal anastomotic leak			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural intestinal perforation			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thermal burn			
subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nervous system disorders</b>			
Headache			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral gas embolism			
subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Tremor			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 217 (0.92%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukocytosis			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Acute vestibular syndrome			
subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo positional			
subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Optic neuropathy			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 217 (0.00%)	2 / 217 (0.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Crohn's disease			
subjects affected / exposed	4 / 217 (1.84%)	14 / 217 (6.45%)	
occurrences causally related to treatment / all	0 / 4	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			

subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fistula			
subjects affected / exposed	3 / 217 (1.38%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocutaneous fistula			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterovesical fistula			
subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer haemorrhage			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			

subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileal stenosis			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal fistula			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	0 / 217 (0.00%)	2 / 217 (0.92%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mechanical ileus			
subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proctitis			

subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal perforation			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subileus			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Acute febrile neutrophilic dermatosis			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erythema nodosum			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Excessive granulation tissue			

subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scar pain			
subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Chronic kidney disease			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	1 / 217 (0.46%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal colic			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fistula			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Myositis			
subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal abscess			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal wall abscess			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess intestinal			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal abscess			
subjects affected / exposed	3 / 217 (1.38%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asymptomatic COVID-19			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			

subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			
subjects affected / exposed	1 / 217 (0.46%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	2 / 217 (0.92%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis norovirus			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	1 / 217 (0.46%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal infection			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis listeria			



subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pilonidal cyst			
subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	2 / 217 (0.92%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal abscess			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal infection			
subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous abscess			

subjects affected / exposed	0 / 217 (0.00%)	1 / 217 (0.46%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrolyte imbalance			
subjects affected / exposed	0 / 217 (0.00%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	1 / 217 (0.46%)	0 / 217 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Placebo Cohort 1	Etrolizumab 105mg Cohort 1	Etrolizumab 105mg Cohort 2
Total subjects affected by non-serious adverse events			
subjects affected / exposed	32 / 59 (54.24%)	61 / 120 (50.83%)	80 / 176 (45.45%)
Nervous system disorders			
Headache			
subjects affected / exposed	4 / 59 (6.78%)	13 / 120 (10.83%)	20 / 176 (11.36%)
occurrences (all)	5	14	27
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 59 (3.39%)	3 / 120 (2.50%)	0 / 176 (0.00%)
occurrences (all)	2	3	0
General disorders and administration			

site conditions			
Fatigue			
subjects affected / exposed	1 / 59 (1.69%)	4 / 120 (3.33%)	6 / 176 (3.41%)
occurrences (all)	1	4	7
Injection site erythema			
subjects affected / exposed	3 / 59 (5.08%)	5 / 120 (4.17%)	9 / 176 (5.11%)
occurrences (all)	5	12	18
Pyrexia			
subjects affected / exposed	0 / 59 (0.00%)	4 / 120 (3.33%)	5 / 176 (2.84%)
occurrences (all)	0	4	5
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 59 (1.69%)	6 / 120 (5.00%)	14 / 176 (7.95%)
occurrences (all)	1	7	16
Crohn's disease			
subjects affected / exposed	12 / 59 (20.34%)	9 / 120 (7.50%)	13 / 176 (7.39%)
occurrences (all)	14	12	13
Diarrhoea			
subjects affected / exposed	1 / 59 (1.69%)	2 / 120 (1.67%)	1 / 176 (0.57%)
occurrences (all)	1	2	1
Dyspepsia			
subjects affected / exposed	2 / 59 (3.39%)	5 / 120 (4.17%)	4 / 176 (2.27%)
occurrences (all)	2	5	4
Frequent bowel movements			
subjects affected / exposed	1 / 59 (1.69%)	1 / 120 (0.83%)	1 / 176 (0.57%)
occurrences (all)	2	2	1
Nausea			
subjects affected / exposed	4 / 59 (6.78%)	7 / 120 (5.83%)	6 / 176 (3.41%)
occurrences (all)	4	8	6
Vomiting			
subjects affected / exposed	2 / 59 (3.39%)	7 / 120 (5.83%)	4 / 176 (2.27%)
occurrences (all)	2	9	5
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	2 / 59 (3.39%)	2 / 120 (1.67%)	2 / 176 (1.14%)
occurrences (all)	3	2	2

Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 59 (3.39%)	6 / 120 (5.00%)	12 / 176 (6.82%)
occurrences (all)	2	6	13
Back pain			
subjects affected / exposed	1 / 59 (1.69%)	3 / 120 (2.50%)	4 / 176 (2.27%)
occurrences (all)	1	3	4
Infections and infestations			
Influenza			
subjects affected / exposed	2 / 59 (3.39%)	2 / 120 (1.67%)	4 / 176 (2.27%)
occurrences (all)	2	2	4
Nasopharyngitis			
subjects affected / exposed	2 / 59 (3.39%)	7 / 120 (5.83%)	11 / 176 (6.25%)
occurrences (all)	2	7	12
Sinusitis			
subjects affected / exposed	1 / 59 (1.69%)	1 / 120 (0.83%)	2 / 176 (1.14%)
occurrences (all)	1	1	2
Upper respiratory tract infection			
subjects affected / exposed	3 / 59 (5.08%)	6 / 120 (5.00%)	11 / 176 (6.25%)
occurrences (all)	3	6	13
Urinary tract infection			
subjects affected / exposed	0 / 59 (0.00%)	3 / 120 (2.50%)	8 / 176 (4.55%)
occurrences (all)	0	3	9

<b>Non-serious adverse events</b>	Etrolizumab 210mg Cohort 1	Etrolizumab 210mg Cohort 2	Placebo/Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	52 / 121 (42.98%)	68 / 174 (39.08%)	33 / 53 (62.26%)
Nervous system disorders			
Headache			
subjects affected / exposed	7 / 121 (5.79%)	20 / 174 (11.49%)	4 / 53 (7.55%)
occurrences (all)	10	22	4
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 121 (1.65%)	5 / 174 (2.87%)	2 / 53 (3.77%)
occurrences (all)	2	5	2
General disorders and administration site conditions			

Fatigue			
subjects affected / exposed	3 / 121 (2.48%)	2 / 174 (1.15%)	1 / 53 (1.89%)
occurrences (all)	3	2	1
Injection site erythema			
subjects affected / exposed	3 / 121 (2.48%)	7 / 174 (4.02%)	2 / 53 (3.77%)
occurrences (all)	7	14	4
Pyrexia			
subjects affected / exposed	4 / 121 (3.31%)	5 / 174 (2.87%)	3 / 53 (5.66%)
occurrences (all)	4	5	3
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	10 / 121 (8.26%)	10 / 174 (5.75%)	9 / 53 (16.98%)
occurrences (all)	12	16	12
Crohn's disease			
subjects affected / exposed	8 / 121 (6.61%)	7 / 174 (4.02%)	13 / 53 (24.53%)
occurrences (all)	9	7	13
Diarrhoea			
subjects affected / exposed	3 / 121 (2.48%)	2 / 174 (1.15%)	2 / 53 (3.77%)
occurrences (all)	3	2	2
Dyspepsia			
subjects affected / exposed	0 / 121 (0.00%)	2 / 174 (1.15%)	2 / 53 (3.77%)
occurrences (all)	0	2	2
Frequent bowel movements			
subjects affected / exposed	0 / 121 (0.00%)	1 / 174 (0.57%)	3 / 53 (5.66%)
occurrences (all)	0	1	5
Nausea			
subjects affected / exposed	8 / 121 (6.61%)	11 / 174 (6.32%)	3 / 53 (5.66%)
occurrences (all)	14	14	7
Vomiting			
subjects affected / exposed	6 / 121 (4.96%)	3 / 174 (1.72%)	0 / 53 (0.00%)
occurrences (all)	8	3	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 121 (0.83%)	1 / 174 (0.57%)	3 / 53 (5.66%)
occurrences (all)	1	1	3
Musculoskeletal and connective tissue disorders			

Arthralgia subjects affected / exposed occurrences (all)	10 / 121 (8.26%) 10	9 / 174 (5.17%) 11	9 / 53 (16.98%) 12
Back pain subjects affected / exposed occurrences (all)	4 / 121 (3.31%) 4	1 / 174 (0.57%) 1	5 / 53 (9.43%) 5
Infections and infestations			
Influenza subjects affected / exposed occurrences (all)	1 / 121 (0.83%) 1	7 / 174 (4.02%) 7	2 / 53 (3.77%) 2
Nasopharyngitis subjects affected / exposed occurrences (all)	9 / 121 (7.44%) 13	7 / 174 (4.02%) 7	3 / 53 (5.66%) 3
Sinusitis subjects affected / exposed occurrences (all)	2 / 121 (1.65%) 2	4 / 174 (2.30%) 4	2 / 53 (3.77%) 2
Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 121 (0.83%) 1	7 / 174 (4.02%) 7	3 / 53 (5.66%) 3
Urinary tract infection subjects affected / exposed occurrences (all)	6 / 121 (4.96%) 7	1 / 174 (0.57%) 1	1 / 53 (1.89%) 1

<b>Non-serious adverse events</b>	Etrolizumab 105mg Cohort 3	Etrolizumab 210mg Cohort 3	Placebo Cohort 3
Total subjects affected by non-serious adverse events subjects affected / exposed	65 / 143 (45.45%)	45 / 145 (31.03%)	35 / 96 (36.46%)
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	14 / 143 (9.79%) 20	8 / 145 (5.52%) 15	7 / 96 (7.29%) 10
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	5 / 143 (3.50%) 5	4 / 145 (2.76%) 4	2 / 96 (2.08%) 2
General disorders and administration site conditions			
Fatigue			

subjects affected / exposed occurrences (all)	4 / 143 (2.80%) 5	5 / 145 (3.45%) 6	3 / 96 (3.13%) 5
Injection site erythema subjects affected / exposed occurrences (all)	6 / 143 (4.20%) 8	5 / 145 (3.45%) 9	0 / 96 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	6 / 143 (4.20%) 8	4 / 145 (2.76%) 4	2 / 96 (2.08%) 2
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	10 / 143 (6.99%) 11	6 / 145 (4.14%) 6	13 / 96 (13.54%) 15
Crohn's disease subjects affected / exposed occurrences (all)	7 / 143 (4.90%) 8	8 / 145 (5.52%) 9	3 / 96 (3.13%) 3
Diarrhoea subjects affected / exposed occurrences (all)	3 / 143 (2.10%) 3	6 / 145 (4.14%) 7	3 / 96 (3.13%) 3
Dyspepsia subjects affected / exposed occurrences (all)	3 / 143 (2.10%) 3	1 / 145 (0.69%) 1	1 / 96 (1.04%) 1
Frequent bowel movements subjects affected / exposed occurrences (all)	1 / 143 (0.70%) 1	0 / 145 (0.00%) 0	1 / 96 (1.04%) 1
Nausea subjects affected / exposed occurrences (all)	6 / 143 (4.20%) 6	6 / 145 (4.14%) 7	8 / 96 (8.33%) 11
Vomiting subjects affected / exposed occurrences (all)	4 / 143 (2.80%) 4	4 / 145 (2.76%) 4	2 / 96 (2.08%) 3
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	1 / 143 (0.70%) 1	2 / 145 (1.38%) 2	4 / 96 (4.17%) 4
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	11 / 143 (7.69%)	7 / 145 (4.83%)	7 / 96 (7.29%)
occurrences (all)	12	8	7
Back pain			
subjects affected / exposed	2 / 143 (1.40%)	0 / 145 (0.00%)	3 / 96 (3.13%)
occurrences (all)	2	0	3
Infections and infestations			
Influenza			
subjects affected / exposed	2 / 143 (1.40%)	0 / 145 (0.00%)	1 / 96 (1.04%)
occurrences (all)	2	0	1
Nasopharyngitis			
subjects affected / exposed	7 / 143 (4.90%)	9 / 145 (6.21%)	4 / 96 (4.17%)
occurrences (all)	9	9	4
Sinusitis			
subjects affected / exposed	4 / 143 (2.80%)	2 / 145 (1.38%)	1 / 96 (1.04%)
occurrences (all)	4	2	1
Upper respiratory tract infection			
subjects affected / exposed	5 / 143 (3.50%)	4 / 145 (2.76%)	1 / 96 (1.04%)
occurrences (all)	5	6	1
Urinary tract infection			
subjects affected / exposed	1 / 143 (0.70%)	2 / 145 (1.38%)	0 / 96 (0.00%)
occurrences (all)	1	2	0

<b>Non-serious adverse events</b>	Etrolizumab/Etrolizumab 105mg	Etrolizumab/Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	147 / 217 (67.74%)	154 / 217 (70.97%)	
Nervous system disorders			
Headache			
subjects affected / exposed	22 / 217 (10.14%)	27 / 217 (12.44%)	
occurrences (all)	27	43	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	11 / 217 (5.07%)	10 / 217 (4.61%)	
occurrences (all)	12	11	
General disorders and administration site conditions			
Fatigue			



subjects affected / exposed occurrences (all)	13 / 217 (5.99%) 15	10 / 217 (4.61%) 11	
Injection site erythema subjects affected / exposed occurrences (all)	7 / 217 (3.23%) 16	14 / 217 (6.45%) 41	
Pyrexia subjects affected / exposed occurrences (all)	7 / 217 (3.23%) 7	16 / 217 (7.37%) 18	
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	27 / 217 (12.44%) 34	24 / 217 (11.06%) 29	
Crohn's disease subjects affected / exposed occurrences (all)	37 / 217 (17.05%) 43	63 / 217 (29.03%) 66	
Diarrhoea subjects affected / exposed occurrences (all)	21 / 217 (9.68%) 22	12 / 217 (5.53%) 15	
Dyspepsia subjects affected / exposed occurrences (all)	8 / 217 (3.69%) 8	11 / 217 (5.07%) 11	
Frequent bowel movements subjects affected / exposed occurrences (all)	1 / 217 (0.46%) 1	2 / 217 (0.92%) 2	
Nausea subjects affected / exposed occurrences (all)	21 / 217 (9.68%) 28	13 / 217 (5.99%) 16	
Vomiting subjects affected / exposed occurrences (all)	14 / 217 (6.45%) 16	12 / 217 (5.53%) 22	
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	7 / 217 (3.23%) 7	4 / 217 (1.84%) 5	
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	27 / 217 (12.44%)	25 / 217 (11.52%)	
occurrences (all)	32	30	
Back pain			
subjects affected / exposed	4 / 217 (1.84%)	10 / 217 (4.61%)	
occurrences (all)	5	10	
Infections and infestations			
Influenza			
subjects affected / exposed	6 / 217 (2.76%)	15 / 217 (6.91%)	
occurrences (all)	6	16	
Nasopharyngitis			
subjects affected / exposed	32 / 217 (14.75%)	27 / 217 (12.44%)	
occurrences (all)	42	35	
Sinusitis			
subjects affected / exposed	13 / 217 (5.99%)	6 / 217 (2.76%)	
occurrences (all)	16	9	
Upper respiratory tract infection			
subjects affected / exposed	16 / 217 (7.37%)	26 / 217 (11.98%)	
occurrences (all)	19	30	
Urinary tract infection			
subjects affected / exposed	11 / 217 (5.07%)	13 / 217 (5.99%)	
occurrences (all)	18	13	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
14 October 2014	V2
09 December 2014	V3
07 October 2015	V4
18 November 2016	V5
31 August 2017	v6
24 April 2019	v7

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/34467254>

<http://www.ncbi.nlm.nih.gov/pubmed/32445184>

<http://www.ncbi.nlm.nih.gov/pubmed/32464142>